This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01243/identifier/national-drug-code-directory/
n17http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/company/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01243/identifier/chemspider/
n18http://bio2rdf.org/drugbank:
n20http://www.drugs.com/cons/
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB01243/identifier/pharmgkb/
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/drug/DB01243/identifier/pubchem-compound/
owlhttp://www.w3.org/2002/07/owl#
n16http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01243/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/drugbank/drug/DB01243/identifier/drugbank/

Statements

Subject Item
n2:DB01243
rdf:type
n3:Drug
n3:description
Chloroxine is a synthetic antibacterial compound. Chloroxine is a compound used in some shampoos for the treatment of dandruff and seborrheic dermatitis of the scalp.
n3:generalReferences
# Malaveille C, Brun G, Bartsch H: Genotoxicity of ochratoxin A and structurally related compounds in Escherichia coli strains: studies on their mode of action. IARC Sci Publ. 1991;(115):261-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1820340 # Malaveille C, Brun G, Bartsch H: Structure-activity studies in E. coli strains on ochratoxin A (OTA) and its analogues implicate a genotoxic free radical and a cytotoxic thiol derivative as reactive metabolites. Mutat Res. 1994 May 1;307(1):141-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7513790
n3:group
approved
n3:indication
Used in the treatment of dandruff and mild to moderately severe seborrheic dermatitis of the scalp.
owl:sameAs
n14:DB01243 n18:DB01243
dcterms:title
Chloroxine
adms:identifier
n7:2722 n9:46508620 n10:0072-6850-04 n11:2621 n12:DB01243 n15:PA164754879
n3:mechanismOfAction
Although the mechanism of action is not understood, chloroxine may slow down mitotic activity in the epidermis, thereby reducing excessive scaling associated with dandruff or seborrheic dermatitis of the scalp. Chloroxine induces SOS-DNA repair in E. coli, so chloroxine may be genotoxic to bacteria.
n3:packager
n5:271B5E25-363D-11E5-9242-09173F13E4C5
n3:synonym
5,7-Dichlor-8-hydroxychinolin 5,7-Dichloro-8-quinolinol 5,7-Dichlorooxine 5,7-Dichloro-8-hydroxyquinoline 5,7-Dichloro-8-oxyquinoline Chlorquinol CHQ 5,7-Dichloroxine
n3:toxicity
The toxicological properties of this material have not been investigated.
n16:hasConcept
n17:M0045392
foaf:page
n20:chloroxine-topical.html
n3:IUPAC-Name
n4:271B5E2A-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5E30-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5E2F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5E2C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5E2D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5E2E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5E28-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5E26-363D-11E5-9242-09173F13E4C5 n4:271B5E29-363D-11E5-9242-09173F13E4C5 n4:271B5E41-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5E27-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5E36-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5E37-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5E31-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5E32-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5E34-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5E33-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5E35-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
773-76-2
n3:category
n3:Bioavailability
n4:271B5E3C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5E3E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5E3F-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5E40-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5E3B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5E3A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5E3D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5E2B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5E38-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5E39-363D-11E5-9242-09173F13E4C5